Oxford Nanopore Technologies has partnered with biomedical database and research resource UK Biobank for an epigenetic study targeting the causes of diseases such as cancer and dementia.
The collaboration aims to analyze the epigenome of 50,000 participant samples. By capturing comprehensive methylation data, the aim is to gain a comprehensive understanding of disease causes and progression, potentially allowing the development of personalized treatments for various diseases,, including cancer and dementia.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.